97 related articles for article (PubMed ID: 15879877)
21. Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities.
Mahmoud AM; Nabavizadeh R; Rodrigues Pessoa R; Garg I; Orme J; Costello BA; Cheville J; Lucien F
Oncologist; 2023 Apr; 28(4):297-308. PubMed ID: 36745503
[TBL] [Abstract][Full Text] [Related]
22. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia.
Leick MB; Silva H; Scarfò I; Larson R; Choi BD; Bouffard AA; Gallagher K; Schmidts A; Bailey SR; Kann MC; Jan M; Wehrli M; Grauwet K; Horick N; Frigault MJ; Maus MV
Cancer Cell; 2022 May; 40(5):494-508.e5. PubMed ID: 35452603
[TBL] [Abstract][Full Text] [Related]
23. Prognostic implication and immunotherapy response prediction of a costimulatory molecule signature in kidney renal clear cell carcinoma.
Lin G; Yang Y; Feng Q; Zhan F; Sun C; Niu Y; Li G
Immunogenetics; 2022 Jun; 74(3):285-301. PubMed ID: 35119508
[TBL] [Abstract][Full Text] [Related]
24. Characterization of CD147, CA9, and CD70 as Tumor-Specific Markers on Extracellular Vesicles in Clear Cell Renal Cell Carcinoma.
Himbert D; Zeuschner P; Ayoubian H; Heinzelmann J; Stöckle M; Junker K
Diagnostics (Basel); 2020 Dec; 10(12):. PubMed ID: 33276608
[TBL] [Abstract][Full Text] [Related]
25. Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Hagemann UB; Wickstroem K; Hammer S; Bjerke RM; Zitzmann-Kolbe S; Ryan OB; Karlsson J; Scholz A; Hennekes H; Mumberg D; Cuthbertson AS
Cancer Biother Radiopharm; 2020 Sep; 35(7):497-510. PubMed ID: 32255671
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive landscape of immune-checkpoints uncovered in clear cell renal cell carcinoma reveals new and emerging therapeutic targets.
Tronik-Le Roux D; Sautreuil M; Bentriou M; Vérine J; Palma MB; Daouya M; Bouhidel F; Lemler S; LeMaoult J; Desgrandchamps F; Cournède PH; Carosella ED
Cancer Immunol Immunother; 2020 Jul; 69(7):1237-1252. PubMed ID: 32166404
[TBL] [Abstract][Full Text] [Related]
27. Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method.
Flieswasser T; Camara-Clayette V; Danu A; Bosq J; Ribrag V; Zabrocki P; Van Rompaey L; de Haard H; Zwaenepoel K; Smits E; Pauwels P; Jacobs J
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31652572
[TBL] [Abstract][Full Text] [Related]
28. Integrated epigenomic profiling reveals endogenous retrovirus reactivation in renal cell carcinoma.
Siebenthall KT; Miller CP; Vierstra JD; Mathieu J; Tretiakova M; Reynolds A; Sandstrom R; Rynes E; Haugen E; Johnson A; Nelson J; Bates D; Diegel M; Dunn D; Frerker M; Buckley M; Kaul R; Zheng Y; Himmelfarb J; Ruohola-Baker H; Akilesh S
EBioMedicine; 2019 Mar; 41():427-442. PubMed ID: 30827930
[TBL] [Abstract][Full Text] [Related]
29. The expansion of targetable biomarkers for CAR T cell therapy.
Townsend MH; Shrestha G; Robison RA; O'Neill KL
J Exp Clin Cancer Res; 2018 Jul; 37(1):163. PubMed ID: 30031396
[TBL] [Abstract][Full Text] [Related]
30. SETDB2 and RIOX2 are differentially expressed among renal cell tumor subtypes, associating with prognosis and metastization.
Ferreira MJ; Pires-Luís AS; Vieira-Coimbra M; Costa-Pinheiro P; Antunes L; Dias PC; Lobo F; Oliveira J; Gonçalves CS; Costa BM; Henrique R; Jerónimo C
Epigenetics; 2017; 12(12):1057-1064. PubMed ID: 29099276
[TBL] [Abstract][Full Text] [Related]
31. Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in
Hagemann UB; Mihaylova D; Uran SR; Borrebaek J; Grant D; Bjerke RM; Karlsson J; Cuthbertson AS
Oncotarget; 2017 Aug; 8(34):56311-56326. PubMed ID: 28915592
[TBL] [Abstract][Full Text] [Related]
32. ATVB Distinguished Scientist Award: How Costimulatory and Coinhibitory Pathways Shape Atherosclerosis.
Ley K; Gerdes N; Winkels H
Arterioscler Thromb Vasc Biol; 2017 May; 37(5):764-777. PubMed ID: 28360089
[TBL] [Abstract][Full Text] [Related]
33. Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.
Greening DW; Ji H; Chen M; Robinson BW; Dick IM; Creaney J; Simpson RJ
Sci Rep; 2016 Sep; 6():32643. PubMed ID: 27605433
[TBL] [Abstract][Full Text] [Related]
34. CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants.
Trebing J; El-Mesery M; Schäfer V; Weisenberger D; Siegmund D; Silence K; Wajant H
Cell Death Dis; 2014 Jan; 5(1):e1035. PubMed ID: 24481449
[TBL] [Abstract][Full Text] [Related]
35. Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas.
Liu N; Sheng X; Liu Y; Zhang X; Yu J
Onco Targets Ther; 2013; 6():615-9. PubMed ID: 23776334
[TBL] [Abstract][Full Text] [Related]
36. Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma.
Chen P; Nogusa S; Thapa RJ; Shaller C; Simmons H; Peri S; Adams GP; Balachandran S
PLoS One; 2013; 8(4):e61446. PubMed ID: 23613854
[TBL] [Abstract][Full Text] [Related]
37. Interferon-γ-induced necrosis: an antitumor biotherapeutic perspective.
Balachandran S; Adams GP
J Interferon Cytokine Res; 2013 Apr; 33(4):171-80. PubMed ID: 23570383
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy targets in pediatric cancer.
Orentas RJ; Lee DW; Mackall C
Front Oncol; 2012; 2():3. PubMed ID: 22645714
[TBL] [Abstract][Full Text] [Related]
39. CD70 expression patterns in renal cell carcinoma.
Jilaveanu LB; Sznol J; Aziz SA; Duchen D; Kluger HM; Camp RL
Hum Pathol; 2012 Sep; 43(9):1394-9. PubMed ID: 22401771
[TBL] [Abstract][Full Text] [Related]
40. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies.
Shaffer DR; Savoldo B; Yi Z; Chow KK; Kakarla S; Spencer DM; Dotti G; Wu MF; Liu H; Kenney S; Gottschalk S
Blood; 2011 Apr; 117(16):4304-14. PubMed ID: 21304103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
